Lowe Brockenbrough & Co. Inc. Cuts Stock Holdings in Pfizer Inc. $PFE

Lowe Brockenbrough & Co. Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 9.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 216,527 shares of the biopharmaceutical company’s stock after selling 22,328 shares during the quarter. Lowe Brockenbrough & Co. Inc.’s holdings in Pfizer were worth $5,214,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Vanguard Group Inc. increased its stake in Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. State Street Corp raised its holdings in shares of Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Morgan Stanley lifted its stake in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Pfizer during the 4th quarter worth about $1,830,986,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $26.77 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company’s fifty day moving average price is $25.12 and its two-hundred day moving average price is $26.20. The firm has a market capitalization of $152.60 billion, a P/E ratio of 35.23 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company posted $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Weiss Ratings restated a “hold (c)” rating on shares of Pfizer in a report on Monday, August 3rd. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and lowered their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.